Pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
The buffer liquid between the two tubes is at a gradually rising concentration, always a bit over the incoming fluid, in this example reaching 1200 mg/L. This is regulated by the pumping action on the returning tube as will be explained immediately. The tip of the loop has the highest concentration of salt (NaCl) in the incoming tube—in the example 1199 mg/L, and in the buffer 1200 mg/L. The returning tube has active transport pumps, pumping salt out to the buffer liquid at a low difference of concentrations of up to 200 mg/L more than in the tube. Thus when opposite the 1000 mg/L in the buffer liquid, the concentration in the tube is 800 and only 200 mg/L are needed to be pumped out. But the same is true anywhere along the line, so that at exit of the loop also only 200 mg/L need to be pumped. In effect, this can be seen as a gradually multiplying effect—hence the name of the phenomena: a 'countercurrent multiplier' or the mechanism: Countercurrent multiplication, but in current engineering terms, countercurrent multiplication is any process where only slight pumping is needed, due to the constant small difference of concentration or heat along the process, gradually raising to its maximum. There is no need for a buffer liquid, if the desired effect is receiving a high concentration at the output pipe.
Increases levels of dehydroepiandrosterone (DHEA) directly by action on the fetal adrenal gland, and indirectly via the mother's pituitary gland. DHEA has a role in preparing for and stimulating cervical contractions. Increases prostaglandin availability in uteroplacental tissues. Prostaglandins activate cervical contractions. Prior to parturition it may have a role inhibiting contractions, through increasing cAMP levels in the myometrium. In culture, trophoblast CRH is inhibited by progesterone, which remains high throughout pregnancy. Its release is stimulated by glucocorticoids and catecholamines, which increase prior to parturition lifting this progesterone block.
Version 1.4a was published in February 2015; the underlying DisplayPort version was updated to 1.3 in order to support HBR3 data rates, Display Stream Compression 1.1, Segmented Panel Displays, and partial updates for Panel Self-Refresh. Version 1.4b was published in October 2015; its protocol refinements and clarifications are intended to enable adoption of eDP 1.4b in devices by mid-2016. Version 1.5 was published in October 2021; adds new features and protocols, including enhanced support for Adaptive-Sync, that provide additional power savings and improved gaming and media playback performance.
=== Inhibition of protein synthesis === The inhibition of protein synthesis is mediated through aminoglycosides' energy-dependent, sometimes irreversible binding, to the cytosolic, membrane-associated bacterial ribosome (image at right). (Aminoglycosides first cross bacterial cell walls—lipopolysaccharide in gram-negative bacteria—and cell membranes, where they are actively transported.) While specific steps in protein synthesis affected may vary somewhat between specific aminoglycoside agents, as can their affinity and degree of binding, aminoglycoside presence in the cytosol generally disturbs peptide elongation at the 30S ribosomal subunit, giving rise to inaccurate mRNA translation and therefore biosynthesis of proteins that are truncated, or bear altered amino acid compositions at particular points. Specifically, binding impairs translational proofreading leading to misreading of the RNA message, premature termination, or both, and so to inaccuracy of the translated protein product. The subset of aberrant proteins that are incorporated into the bacterial cell membrane may then lead to changes in its permeability and then to "further stimulation of aminoglycoside transport". The amino sugar portion of this class of molecules (e.g., the 2-deoxystreptamine in kanamycins, gentamicins, and tobramycin, see above) are implicated in the association of the small molecule with ribosomal structures that lead to the infidelities in translation (ibid.). Inhibition of ribosomal translocation—i.e., movement of the peptidyl-tRNA from the A- to the P-site—has also been suggested.
=== Second formation === The division was reconstituted starting in March 1945 and placed under the operational control of the 2nd Army (Army Group Vistula) in West Prussia. On 10 March 1945, the division was reformed near Schwedt with only two regiments. The "Shadow Division Hannover" was utilized for this purpose. Grenadier Regiment 1093 was not re-established, and the artillery regiment consisted of only a single battalion. Subsequently, the division was assigned to the 3rd Panzer Army and deployed on the Oder front against the Red Army. In May 1945, the 547th Volksgrenadier Division surrendered to US forces near Schwerin in Mecklenburg.
Sources: en.wikipedia.org
She has been affiliated with Brigham and Women's Hospital and is a member of the intramural faculty at the Koch Institute for Integrative Cancer Research. She served on the National Cancer Institute (NCI) Board of Scientific Advisors and co-led the first synthetic biomarker think tank at the NCI (SYNDICATE) with the late Sanjiv Gambhir. She also co-chaired the first AACR conference on Precision Prevention, Early Detection, and Interception of Cancer, and the annual Irwin M. Arias Symposium, a leading event in liver research.
==== Parafollicular cells ==== Scattered among follicular cells and in spaces between the spherical follicles are another type of thyroid cell, parafollicular cells. These cells secrete calcitonin and so are also called C cells.
From the time of Maria Theresa (1740−1780) onward, Tyrol was governed by the central government of the Habsburg monarchy at Vienna in all matters of major importance. In 1803 the lands of the Prince-Bishoprics of Trent and Brixen were secularised and incorporated into the county.
=== Books === Square One: A Simple Guide to a Balanced Life Maroon J, Kennedy C. (2017) ISBN 978-0-9983509-0-5 The Longevity Factor: How Resveratrol and Red Wine Activate Genes for a longer and Healthier Life Maroon JC. (2008) ISBN 9781416565161 (made into a PBS Special) Fish Oil: The Natural Anti-Inflammatory Maroon JC, Bost J. (2006) ISBN 9781591201823 Practice Diagnosis and Management of Orbital Disease Kennerdell JS, Cockerham KP, Maroon JC, Rothfus WE. (2001) ISBN 9780750672603 What You Can Do About Cancer. Maroon JC. (1969) Doubleday& Co., New York, 185 pp. (English, Italian, German and French translations).
Sources: en.wikipedia.org
An important task within the realm of food safety is the elimination of microorganisms responsible for food-borne illness. Food and waterborne diseases still pose a serious health concern, with hundreds of outbreaks reported per year since 1971 in the United States alone. The risk of these diseases has risen throughout the years, mainly due to the mishandling of raw food, poor sanitation, and poor socioeconomic conditions. In addition to diseases caused by direct infection by pathogens, some food borne diseases are caused by the presence of toxins produced by microorganisms in food. There are five main types of microbial pathogens which contaminate food and water: viruses, bacteria, fungi, pathogenic protozoa and helminths. Several bacteria, such as E. coli, Clostridium botulinum, and Salmonella enterica, are well-known and are targeted for elimination via various industrial processes. Though bacteria are often the focus of food safety processes, viruses, protozoa, and molds are also known to cause food-borne illness and are of concern when designing processes to ensure food safety. Although the goal of food safety is to eliminate harmful organisms from food and prevent food-borne illness, detecting said organisms is another important function of food safety mechanisms.
== In tomatoes == Some, such as the California Poison Control Center, have claimed that unripe tomatoes and tomato leaves contain solanine. However, Mendel Friedman of the United States Department of Agriculture contradicts this claim, stating that tomatine, a relatively benign alkaloid, is the tomato alkaloid while solanine is found in potatoes. Food science writer Harold McGee has found scant evidence for tomato toxicity in the medical and veterinary literature.
=== Use of paper microfluidics in blood grouping === Recently, paper microfluidics was used in the fabrication of numerous immunological tests. Khan et al. in 2010 investigated a blood typing device based on the principle that red blood cell agglutination, triggered by specific antigeninteraction, drastically decreases blood wicking and transport on paper or chromatographic media. The concept was exhibited with a paper-based microfluidic device prototype, made from a filter paper shaped to a central zone with three extending channels. Each channel is treated with a different solution of antibody (Epiclone Anti-A, Anti-B, and Anti-D). Since μPADs were purposely created for use in resource-shortage conditions, it is highly important to provide the capability to analyze real samples like non-pretreated human blood and urine. This device is constructed to analyze whole-blood samples, which is an important step to increase the user acceptance of paper-based microfluidic diagnostics. The analysis is based on the wicking behavior of blood or antibody mixture on paper. Mixing blood samples with immunoglobulin M antibodies, specific for each blood group, causes agglutination of the red blood cells (RBC) by polymer bridging upon adsorption on the corresponding RBC antigens, and chromatographic separation of sample on the certain channel of the device occurs. Simultaneously, separation doesn't happen on hands soaked in non-specific antibody and the blood sample is weakened as a uniform and stable solution.
S100 calcium-binding protein B (S100B) is a protein of the S100 protein family. S100 proteins are localized in the cytoplasm and nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21; however, this gene is located at 21q22.3.
== Recreational use == In 1979, the first case of xylazine toxicity was reported in a 34-year-old male who had self-medicated for insomnia with an injection of 1g of xylazine. In the US, Xylazine is not regulated as a controlled substance under the Controlled Substances Act. It is sold online through distributors often without requiring proof of a veterinary license. The cost to purchase Xylazine from overseas suppliers is around $6–20 per kilogram. This low price makes it attractive for dealers looking for a cheap additive that is addictive and not treatable with opiate withdrawal medications. The withdrawal can last for two weeks and has a quicker onset than fentanyl. As an adulterant, xylazine is most commonly ingested with fentanyl. Xylazine has also been reported in combination with medetomidine, another potent α2-adrenergic receptor agonist. It is unknown if drug users are ingesting it knowingly. As of 2024, Seattle police report that some users wrongly believe they are consuming higher-quality fentanyl. Xylazine's street name in Puerto Rico is anestesia de caballo, which translates to "horse anesthetic". From 2002 to 2008, its use was associated with a high number of inmate deaths at the Guerrero Correctional Institution in Aguadilla, Puerto Rico. Xylazine's street name in the United States, particularly when it is mixed with fentanyl, is "tranq", "tranq dope" and "zombie drug". As of 2012, xylazine users in Puerto Rico were more likely to be male, under age 30, living in a rural area, and injecting rather than inhaling xylazine.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.